Company: LIMN
Filing Date: 2025-07-28
Form Type: S-1/A
Source: 0001410578-25-001518
Chunk: 308

Company: Liminatus Pharma, Inc.
Filing Date: 2025-07-28
Form: S-1/A
Chunk 308
---
 ​ |
| Stockholders’ Deficit                                                                                                                                                                                                                          | ​ |              |             | ​ |      |             |
| Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding                                                                                                                                                   | ​ |              |           — | ​ |      |           — |
| Class A common stock, $0.0001 par value; 280,000,000 shares authorized; 6,900,000 shares issued and outstanding (excluding 174,477 and 406,609 shares subject to possible redemption, respectively) at December 31, 2024 and December 31, 2023 | ​ |              |         690 | ​ |      |         690 |
| Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 0 shares issued and outstanding at December 31, 2024 and December 31, 2023                                                                                              | ​ |              |           — | ​ |      |           — |
| Extension deposits due from Sponsor                                                                                                                                                                                                            | ​ | ​            |    -160,677 | ​ | ​    |           — |
| Additional paid-in capital                                                                                                                                                                                                                     | ​ |              |      51,795 | ​ |      |     140,000 |
| Accumulated deficit                                                                                                                                                                                                                            | ​ |              | -17,518,175 | ​ |      | -14,883,124 |
| Total Stockholders’ Deficit                                                                                                                                                                                                                    | ​ |              | -17,626,367 | ​ |      | -14,742,434 |
| Total Liabilities, Common Stock Subject to Possible Redemption and Stockholders’ Deficit                                                                                                                                                       | ​ | $            |   2,828,932 | ​ | $    |   4,502,213 |

| (1) | As of December 31, 2024 and December 31, 2023, include $12,347 and $85,084, respectively of the restricted cash to be used for tax payments only. |

The accompanying notes are an integral part of these financial statements.

F-78

IRIS ACQUISITION CORP STATEMENTS OF OPERATIONS

| ​                                                                                                          
 ​                                                                                                          | ​ 
 ​ 
 ​ | ​                                
 For the years ended December 31, |          ​ 
       2024 | ​ | ​ 
 ​ |          ​ 
       2023 |
|:-----------------------------------------------------------------------------------------------------------|:--|: